About AVT
Browse Articles
Authors
Customer Services

Advanced Publication

Antiviral Therapy publishes articles here before they are finally assigned to an issue. The articles are listed by online publication date and can be cited via a doi.
 
Displaying 56 results:

Original article

Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

Lisa I Backus, Pamela S Belperio, Troy A Shahoumian, Timothy P Loomis, Larry A Mole

10.3851/IMP3117


Short communication

Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial

Juergen K Rockstroh, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Rebecca Zhang-Roper, Ronnie Wang, Juan A Pineda, Jayvant Heera

10.3851/IMP3116


Original article

Activity of Ergoferon against lethal influenza A (H3N2) virus infection in mice

Maria A Skarnovich, Alexandra G Emelyanova, Nataliia V Petrova, Alena A Borshcheva, Evgeniy A Gorbunov, Oleg Yu Mazurkov, Maksim O Skarnovich, Sergey A Tarasov, Larisa N Shishkina, Oleg I Epstein

10.3851/IMP3115


Original article

A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada

Anita C Benoit, Jaime Younger, Kerrigan Beaver, Randy Jackson, Mona Loutfy, Renée Masching, Tony Nobis, Earl Nowgesic, Doe O’Brien-Teengs, Wanda Whitebird, Art Zoccole, Mark Hull, Denise Jaworsky, Anita Rachlis, Sean Rourke, Ann N Burchell, Curtis Cooper, Robert Hogg, Marina B Klein, Nima Machouf, Julio Montaner, Chris Tsoukas, Janet Raboud, Building Bridges and the Canadian Observational Cohort Collaboration

10.3851/IMP3114


Original article

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial

Melanie Thompson, Jacob P Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, Pedro Cahn, David A Stock, Samit R Joshi, George J Hanna, Max Lataillade, the AI438011 study team

10.3851/IMP3112


Case report

Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?

Julien Lupo, Ophélie Dos Santos, Raphaele Germi, Monique Baccard-Longère, Jean-Paul Stahl, Olivier Epaulard, Patrice Morand

10.3851/IMP3110


Correction

Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort

Amedeo F Capetti, Gaetana Sterrantino, Maria V Cossu, Giovanni Cenderello, Anna M Cattelan, Giuseppe V De Socio, Stefano Rusconi, Niccolò Riccardi, Gian M Baldin, Serena Cima, Fosca P Niero, Giuliano Rizzardini, Lolita Sasset

10.3851/IMP3109


Original article

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV–HCV coinfection and advanced liver disease

Jürgen K Rockstroh, Patrick Ingiliz, Jörg Petersen, Markus Peck-Radosavljevic, Tania M Welzel, Marc Van der Valk, Yue Zhao, Maria Jesus Jimenez Exposito, Stefan Zeuzem

10.3851/IMP3108


Case report

Early neuropsychological adverse events after switching from PI/r to dolutegravir could be related to hyperthyroidism in patients under levothyroxine

Jean-Luc Berger, Yohan Nguyen, Delphine Lebrun, Caroline Migault, Maxime Hentzien, Hélène Marty, Firouzé Bani-Sadr

10.3851/IMP3107


Original article

Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials

Nivashnee Naicker, Anushka Naidoo, Lise Werner, Nigel Garrett, Nelisile Majola, Villeshni Asari, Cheryl Baxter, Anneke Grobler, Quarraisha Abdool Karim, Salim S Abdool Karim

10.3851/IMP3106


Page:
Copyright © Nucleus Global 2016. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.